Archeon Medical raises €7.5 million to push EOlife into US market
What's the deal? Archeon MedicalDealroom has a profile for this one. Try Dealroom →, a Besançon, France-based maker of an emergency ventilation monitoring platform, has raised €7.5 million in Series A funding. NewfundDealroom has a profile for this one. Try Dealroom → led the round through its HEKA fundDealroom has a profile for this one. Try Dealroom →, with Eiffel Investment GroupDealroom has a profile for this one. Try Dealroom →, UI InvestissementDealroom has a profile for this one. Try Dealroom →, Majycc Innovation Santé, and Karot CapitalDealroom has a profile for this one. Try Dealroom → participating.
What's the endgame? The company's lead product, EOlife, is a real-time feedback device that measures the air volume delivered to a cardiac arrest patient's lungs. It offers visual guidance to help responders avoid hyperventilation and under-ventilation.
Why now? Archeon Medical holds both FDA clearance and CE mark approval, and already operates in European and US markets. It will use the new funding to accelerate US clinical validation and expand commercial efforts.
The signal: At €7.5 million, the round sits in the mid-tier of early-stage medtech deals — enough to fund a focused US push without the burn of a larger raise. For Archeon, led by chief executive officer Alban de Luca, the bet is that proving clinical value stateside unlocks its biggest growth market.
Read more: finsmes.com
Image credit: Archeon Medical
